Comparative Study of Quinine Sulfate in Healthy Patients and in Patients With Renal Impairment
Status:
Terminated
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
The effects of mild or moderate renal impairment (creatinine clearance 30 to 50 ml/min or >50
to 80 ml/min, respectively) on the pharmacokinetic profile of quinine and its active
metabolite, 3'-hydroxyquinine, will be investigated. Safety and tolerability in healthy
subjects versus those with mild to moderate renal impairment will be compared, as well.